Temedica Expands Advisory Board with Ex-Gematik CEO Markus Leyck Dieken

Munich-based health insights company, Temedica, has announced the addition of Dr. med. Markus Leyck Dieken to its Advisory Board. Leyck Dieken, the former CEO of Gematik, brings extensive experience in healthcare digital transformation. He will focus on strategic-regulatory issues at Temedica, leveraging his expertise in internal and emergency medicine, biotechnological product development and healthcare policy.

During his career, Leyck Dieken has held prominent roles, including leading the development of diabetes therapies at Novo Nordisk and managing the EU vaccine business at Novartis. He also contributed to combating antibiotic resistance at Shionogi Europe. His tenure as CEO of Gematik was marked significant advancements in Germany’s healthcare system through digital innovations.

Gloria Seibert, CEO of Temedica, emphasized that Leyck Dieken’s addition is a strategic asset, enhancing the company's capabilities in real-world evidence and personalized medicine. Leyck Dieken himself highlighted the potential of digital tools to revolutionize patient care through real-world evidence.